Medical Marijuana, Inc. Applauds Mexican Congress’ Passage of Legislation to Legalize Usage of Medical Marijuana in Mexico

SAN DIEGO, May 1, 2017 /PRNewswire/ — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that it applauds the Mexican Congress for passing legislation on April 28 to legalize the use of marijuana and cannabis for medical and scientific needs in Mexico.

The bill, which overwhelmingly passed in a general floor vote with 371 in favor, seven against and 11 abstentions, will now be sent to Mexican President Enrique Pena Nieto to be signed into law.

 According to the Mexican Lower House of Congress, the ruling “eliminates the prohibition and criminalization of acts related to the medicinal use of marijuana and its scientific research, and those relating to the production and distribution of the plant for these purposes.”

“We applaud Mexico lawmakers for taking this significant step to reform cannabis laws to benefit their citizens,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “We are extremely proud to have been the first company to provide Mexico citizens with legal access to a medical product based on cannabis (THC-free hemp CBD). We believe the successful implementation of our product within Mexico, plus the overwhelming success of our clinical studies have helped to change the dialogue within the country regarding the safety and therapeutic potential of all forms of cannabis.”

“Given the Mexican Congress’ decision today, we are looking forward to the opportunity to assist an increasing number of citizens that suffer from unsuccessfully treated, debilitating medical conditions,” continued Dr. Titus. “Furthermore, we commend Mexican President Enrique Pena Nieto’s initiative to reform Mexico’s General Health Law and the country’s Federal Penal Code to continue relaxing laws against the medicinal use of cannabis. With the Mexico Congress’ decision today, families will experience fewer roadblocks when it comes to gaining access within the country.”

Medical Marijuana, Inc., started exporting to Mexico to help families gain access to THC-free CBD hemp oil Real Scientific Hemp Oil™ (RSHO-X™), after the Health Department of Mexico, COFEPRIS, issued the country’s first-ever government permits on February 2, 2016, to two families, including the Maldonado family whose daughter suffered from a severe form of epilepsy.

Medical Marijuana, Inc. created its subsidiary HempMeds® Mexico after RSHO-X™ product became the first and only cannabis product allowed for import into the country. HempMeds® Mexico works side by side with doctors, patients, and policy makers in Mexico to ensure those in need of cannabidiol (CBD) have access to it.

Follow the link here for more information on HempMeds® Mexico and here for its historic first-year milestones.

About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About HempMeds®
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company, handling sales and distribution.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.



Blunt: Curating the Cannabis Content you Need the Most

SIGN UP FOR FREE POST ALERTS!

We keep your data private and do not share your information with anyone.